IAG, Image Analysis Group & Collaborators Present Latest Data at ACR 2020
A number of abstracts by IAG’s team and scientific and industry collaborators were accepted for presentation at the American College of Rheumatology Annual Meeting, 2020. This global meeting brings together researchers, clinicians and industry and facilitates boundless opportunities for professional development, networking, and first-hand access to the latest rheumatology research and clinical applications.
IAG’s accepted abstracts present the data from the latest clinical research trials and Investigator Initiated Studies and involve state-of-the-art and cutting-edge advanced imaging techniques, our quantitative methodologies for assessment of treatment efficacy, including some that are based on Machine Learning and AI principals.
The accepted abstracts are:
Role of Artificial Intelligence in Assessment of Peripheral Joint MRI in Inflammatory Arthritis: A Systematic Review and Meta-analysis. Arya Haj-Mirzaian, Olga Kubassova, Mikael Boesen, Paul Bird, John A. Carrino
SESSION INFORMATION
Date: Monday, November 9, 2020
Session Title: Imaging of Rheumatic Diseases Poster
Session Type: Poster Session D
Session Time: 9:00AM-11:00AM
This paper discussed AI-based methods for MRI, Contrast Enhanced MRI and Dynamic Contrast Enhanced MRI, used in 28 Rheumatoid Arthritis clinical studies, where 1342 MRIs were analyzed. Our meta-regression analysis showed that computer-aided and manual methods provide comparable reliability for quantification of bone erosion, synovitis, and perfusion parameters (P>0.05) and that AI-based methods demonstrate feasibility, reliability and validity when utilized to quantify MRI pathologies of peripheral joints in patients with inflammatory
Evaluation of a Patient-reported Frailty Tool in Women with Systemic Lupus Erythematosus.
Sarah Lieber, Stephen Paget, Jessica Berman, Medha Barbhaiya, Lisa Sammaritano, Kyriakos Kirou, John Carrino, Musarrat Nahid, Mangala Rajan, Dina Sheira and Lisa Mandl
SESSION INFORMATION
Date: Sunday, November 8, 2020
Session Title: SLE – Diagnosis, Manifestations, & Outcomes Poster II: Comorbidities
Session Type: Poster Session C
Session Time: 9:00AM-11:00AM
This abstract presents a patient-reported frailty tool and evaluates it alongside a standard frailty measure in SLE. With the data from 72 female patients, the abstract discusses 1) the prevalence of frailty according to both the standard Fried phenotype (FP) and a validated self-reported frailty instrument, 2) differences between frail and non-frail women according to each definition, 3) the association of each frailty measure with patient-reported disability, and 4) the correlation between frailty definitions.
Digital Artery Volume Index (Davix©) Predicts Onset of Future Digital Ulcers in Patients with Systemic Sclerosis, Klodian Gjeloshi, Giovanni Lettieri, Fiammetta Danzo, Giuseppina Abignano, Mark Hinton, Anne-Maree Dean, Giovanna Cuomo, Olga Kubassova and Francesco Del Galdo
SESSION INFORMATION
Date: Sunday, November 8, 2020
Session Title: Systemic Sclerosis & Related Disorders – Clinical Poster III
Session Type: Poster Session C
Session Time: 9:00AM-11:00AM
This abstract work is a continuation of our work on development and validation of digital artery volume index (DAVID). This study demonstrates that DAVIX© is a feasible surrogate outcome measure of neointima proliferation in SSc and a useful predictive imaging biomarker of vascular disease activity.
Doppler Ultrasound Predicts Successful Discontinuation of Biological DMARDs in Rheumatoid Arthritis Patients in Sustained Clinical Remission. Lene Terslev, Cecilie Hegaard Brahe, Merete Hetland, Stylianos Georgiadis, Karen Ellegaard, Lars Juul, Uffe Døhn, Viktoria Fana, Torsten Møller, Simon Krabbe, Lykke Ørnbjerg, Daniel Glinatsi, Tuan Khai Huynh, Natalia Manilo, Dorte Vendelbo Jensen, Karsten Asmussen, Mikael Boesen, Zoreh Rastiemadabadi, Lone Morsel-Carlsen, Jakob Møller, Henrik Røgind, Annette Hansen, Jesper Nørregaard, Søren Jacobsen, Niels Steen Krogh and Mikkel Østergaard,
SESSION INFORMATION
Date: Monday, November 9, 2020
Session Title: Imaging of Rheumatic Diseases Poster
Session Type: Poster Session D
Session Time: 9:00AM-11:00AM
There is an increasing interest in tapering or even discontinuing biological disease-modifying anti-rheumatic drugs (bDMARDs) in rheumatoid arthritis (RA) patients in sustained remission. This abstract, co-authored by two members of IAG’s Scientific Advisory Board aims to assess the potential role of ultrasound for predicting successful tapering and successful discontinuation.
Weight Loss as Treatment for Gout in Patients with Concomitant Obesity: A Proof-of-Concept Randomized Controlled Trial. Kristian Zobbe, Robin Christensen, Sabrina Mai Nielsen, Lisa Stamp, Marius Henriksen, Anders Føhrby Overgaard, Lene Dreyer, Filip Krag Knop, Jasvinder Singh, Michael Doherty, Pascal Richette, Arne Astrup, Karen Ellegaard, Else Marie Bartels, Mikael Boesen, Henrik Rindel Gudbergsen, Henning Bliddal and Lars Erik Kristensen.
SESSION INFORMATION
Date: Saturday, November 7, 2020
Session Title: Metabolic & Crystal Arthropathies Poster
Session Type: Poster Session B
Session Time: 9:00AM-11:00AM
This is a study of an intensive dietary intervention showing that it can effectively lower body weight in people with gout and concomitant obesity.
We look forward to this exciting meeting, in a new virtual format! Warmest thanks to our collaborators, scientific advisors and biotechnology and pharmaceutical partners for their contributions.
If you are planning a clinical trial to treat #lupus, inflammatory #arthritis, #gout, #osteoarthritis and other musculoskeletal and rheumatic diseases, speak to our expert team!
Email: imaging.experts@ia-grp.com
About Image Analysis Group (IAG)
IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.
Learn more: wp1.ia-grp.com
Reach out: imaging.experts@ia-grp.com
Follow the Company: Linkedin